Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:ETHZ NASDAQ:KPTI NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.17+7.3%$0.74$0.40▼$2.36$58.37M1.111.67 million shs281,295 shsETHZFlag Ship Acquisition$2.47+1.2%$0.00$0.66▼$17.75$14.74M0.3719.76 million shs9.70 million shsKPTIKaryopharm Therapeutics$6.21-1.9%$5.16$3.51▼$16.95$54.89M0.35191,091 shs79,538 shsPDSBPDS Biotechnology$1.23+4.2%$1.20$0.85▼$4.29$55.49M1.15554,587 shs331,296 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology+7.34%+14.71%+90.40%+116.39%-45.83%ETHZFlag Ship Acquisition+1.23%-1.98%+246,999,900.00%+246,999,900.00%+246,999,900.00%KPTIKaryopharm Therapeutics-1.90%-12.29%+64.72%+42.43%-42.89%PDSBPDS Biotechnology+4.24%-5.38%+13.89%-31.28%-59.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.17+7.3%$0.74$0.40▼$2.36$58.37M1.111.67 million shs281,295 shsETHZFlag Ship Acquisition$2.47+1.2%$0.00$0.66▼$17.75$14.74M0.3719.76 million shs9.70 million shsKPTIKaryopharm Therapeutics$6.21-1.9%$5.16$3.51▼$16.95$54.89M0.35191,091 shs79,538 shsPDSBPDS Biotechnology$1.23+4.2%$1.20$0.85▼$4.29$55.49M1.15554,587 shs331,296 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology+7.34%+14.71%+90.40%+116.39%-45.83%ETHZFlag Ship Acquisition+1.23%-1.98%+246,999,900.00%+246,999,900.00%+246,999,900.00%KPTIKaryopharm Therapeutics-1.90%-12.29%+64.72%+42.43%-42.89%PDSBPDS Biotechnology+4.24%-5.38%+13.89%-31.28%-59.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.83Moderate Buy$3.30182.05% UpsideETHZFlag Ship Acquisition 0.00N/AN/AN/AKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00447.50% UpsidePDSBPDS Biotechnology 3.00Buy$10.00713.01% UpsideCurrent Analyst Ratings BreakdownLatest ETHZ, KPTI, ALXO, and PDSB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $25.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.007/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/AETHZFlag Ship AcquisitionN/AN/AN/AN/A$2.91 per shareN/AKPTIKaryopharm Therapeutics$145.24M0.37N/AN/A($22.10) per share-0.28PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$134.85M-$2.20N/AN/AN/AN/A-115.67%-84.82%11/6/2025 (Estimated)ETHZFlag Ship Acquisition-$6.17M-$15.070.00∞N/AN/A-141.25%-80.77%N/AKPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%11/13/2025 (Estimated)Latest ETHZ, KPTI, ALXO, and PDSB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24-$0.21+$0.03-$0.21N/AN/A8/12/2025Q2 2025ALXOALX Oncology-$0.46-$0.49-$0.03-$0.49N/AN/A8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.114.524.52ETHZFlag Ship AcquisitionN/A0.580.58KPTIKaryopharm TherapeuticsN/A0.990.94PDSBPDS Biotechnology0.812.922.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%ETHZFlag Ship Acquisition4.07%KPTIKaryopharm Therapeutics66.44%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%ETHZFlag Ship Acquisition38.20%KPTIKaryopharm Therapeutics2.98%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology4053.55 million42.31 millionOptionableETHZFlag Ship Acquisition76.04 million3.73 millionN/AKPTIKaryopharm Therapeutics3808.67 million8.41 millionOptionablePDSBPDS Biotechnology2047.03 million42.70 millionOptionableETHZ, KPTI, ALXO, and PDSB HeadlinesRecent News About These CompaniesArmistice Capital LLC Acquires Shares of 4,419,000 PDS Biotechnology Corporation $PDSBSeptember 2, 2025 | marketbeat.comPDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comPDS Biotechnology Announces Promising Phase 2 Trial ResultsAugust 25, 2025 | msn.comPDS Biotechnology announces data from its VERSATILE-002 Phase 2 trialAugust 25, 2025 | msn.comPDS Biotechnology stock rises after announcing promising cancer trial dataAugust 25, 2025 | za.investing.comPDS Biotechnology Reports 39.3-Month Median Overall Survival in VERSATILE-002 Trial for HPV16-Positive Head and Neck CancerAugust 25, 2025 | quiverquant.comQPDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerAugust 25, 2025 | manilatimes.netMPDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerAugust 25, 2025 | globenewswire.comQ3 EPS Forecast for PDS Biotechnology Boosted by AnalystAugust 17, 2025 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comBiotech Stocks Rally as Oncology Market Targets $866B by 2034August 14, 2025 | prnewswire.co.ukPPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comPDS Biotechnology Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comPDS Biotechnology reports Q2 EPS (21c), consensus (23c)August 13, 2025 | msn.comPDS Biotechnology: Q2 Earnings SnapshotAugust 13, 2025 | stamfordadvocate.comSPDSB Loss Improves as Costs DropAugust 13, 2025 | aol.comAPDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs UpdateAugust 13, 2025 | globenewswire.comInsights into PDS Biotechnology's Upcoming EarningsAugust 12, 2025 | benzinga.comPDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comPDS wasn’t a bad deal, few greedy individuals cannibalised it with self-serving interests – John JinaporJuly 16, 2025 | modernghana.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETHZ, KPTI, ALXO, and PDSB Company DescriptionsALX Oncology NASDAQ:ALXO$1.17 +0.08 (+7.34%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$1.16 -0.01 (-0.85%) As of 09/10/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Flag Ship Acquisition NASDAQ:ETHZ$2.47 +0.03 (+1.23%) As of 09/10/2025 04:00 PM Eastern1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Karyopharm Therapeutics NASDAQ:KPTI$6.21 -0.12 (-1.90%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$6.19 -0.02 (-0.32%) As of 09/10/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.PDS Biotechnology NASDAQ:PDSB$1.23 +0.05 (+4.24%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$1.22 -0.01 (-0.81%) As of 09/10/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
